Sangamo Therapeutics Inc. (SGMO)
Symbol Info
Listed Symbol SGMO
Name Sangamo Therapeutics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $84,452,000
Latest Fiscal EPS $-0.71
Price Info
21 Day Moving Average $8.8886
21 Day EMA $8.894460
50 Day Moving Average $10.1526
50 Day EMA $9.737280
200 Day EMA $10.953660
200 Day Moving Average 10.524800
52 Week High $14.58
52 Week Low $6.26
52 Week Change $-41.402400
Alpha -0.007238
Beta 2.7835
Standard Deviation 0.199472
R2 0.229646
Periods 60
Share Information
10 Day Average Volume 1,513,441
20 Day Average Volume 1,337,755
30 Day Average Volume 1,217,331
50 Day Average Volume 1,201,257
Outstanding Shares 115,675,077
Float Shares 113,597,471
Percent Float 98.20%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 393
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 20,549,319
Institute Holdings Percent 99.100000
Institute Sold Previous 3 Months 6,121,022
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 14
Insider Holdings Percent 1.80%
Insider Sold Previous 3 Months -
Insiders Shares Owned 2,077,606
Price Change
7 Day Price Change $0.1149998
7 Day Percent Change 1.40%
21 Day Price Change $-0.875
21 Day Percent Change -9.52%
30 Day Price Change $-2.4550009
30 Day Percent Change -22.79%
Month To Date Price Change $-0.735
Month To Date Percent -8.12%
90 Day Price Change $-3.835
90 Day Percent Change -31.56%
Quarter To Date $-0.735001
Quarter To Date Percent -8.12%
180 Day Price Change $-3.385
180 Day Percent Change -28.93%
200 Day Price Change $-1.215
200 Day Percent Change -12.75%
Year To Date $-3.165
Year To Date Percent -27.57%
Profile
Description Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.
Details
Issue Type CS
Market Cap $961,838,265
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 115,675,077
CEO Alexander Macrae
Employees 302
Last Audit UE
Classification
CIK 0001001233
Industry Biotechnology
Sector Healthcare
NAICS Biological Product (except Diagnostic) Manufacturing(325414)
Info
Address 501 Canal Boulevard
Richmond, CA 94804
Website https://www.sangamo.com
Facisimile +1 510 236-8951
Telephone +1 510 970-6000
Email mstilwell@sangamo.com
Key Ratios
Profitability
EBIT Margin -150.5
EBITDA Margin -146.9
Pre-Tax Profit Margin -155.1
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $52,456,000
Revenue Per Share $0.4535
Revenue 3 Years $50.59
Revenue 5 Years $8.98
Valuation Measures
PE Ratio -
Enterprise Value $647,310,446
Price To Sales 18.336096
Price To Free Cash -4.2
PE High Last 5 Years -
Price To Book 2.3
Price To Cash Flow 119.2
PE Low Last 5 Years -
Price To Tangible Book 2.9
Financial Strength
Total Debt To Equity 0.1
Int Coverage -
Current Ratio 5.6
Leverage Ratio 1.6
Quick Ratio 5.5
Long Term Debt To Capital 0.09
Assets
Receivables Turnover 3.3
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -15.98
Return On Equity -24.96
Return On Capital -23.08
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
SGMO
Sangamo Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.